Literature DB >> 10570754

Changes in prefrontal cortex and paralimbic activity in depression following two weeks of daily left prefrontal TMS.

C C Teneback1, Z Nahas, A M Speer, M Molloy, L E Stallings, K M Spicer, S C Risch, M S George.   

Abstract

Twenty-two depressed adults were scanned with perfusion single-photon computed emission tomography before and after 2 weeks of left perfrontal transcranial magnetic stimulation (TMS) in a parallel design, double-blind treatment study. At medication-free baseline, across all subjects, blood flow in the bilateral medial temporal lobes, left prefrontal cortex, and caudate significantly declined with increased depression severity. Also at baseline, depressed adults who responded to TMS, compared with nonresponders, showed increased inferior frontal lobe activity. Following treatment, there was an even greater difference in inferior frontal blood flow in responders compared with nonresponders, and the negative baseline correlations between depression severity and limbic and prefrontal blood flow disappeared. These results suggest that in depressed adults, 10 days of prefrontal TMS affects prefrontal and paralimbic activity, which may explain its antidepressant effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570754     DOI: 10.1176/jnp.11.4.426

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  49 in total

Review 1.  Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex.

Authors:  Rita Z Goldstein; Nora D Volkow
Journal:  Am J Psychiatry       Date:  2002-10       Impact factor: 18.112

Review 2.  Transcranial magnetic stimulation: studying motor neurophysiology of psychiatric disorders.

Authors:  Fumiko Maeda; Alvaro Pascual-Leone
Journal:  Psychopharmacology (Berl)       Date:  2003-06-26       Impact factor: 4.530

3.  Fast left prefrontal rTMS acutely suppresses analgesic effects of perceived controllability on the emotional component of pain experience.

Authors:  Jeffrey J Borckardt; Scott T Reeves; Heather Frohman; Alok Madan; Mark P Jensen; David Patterson; Kelly Barth; A Richard Smith; Richard Gracely; Mark S George
Journal:  Pain       Date:  2010-11-30       Impact factor: 6.961

4.  Neuromodulation and Transcranial Mag Netic Stimulation (TMS): A 21st Century Paradigm for Therapeutics in Psychiatry.

Authors:  John P O'Reardon; Andrew D Peshek; Rocio Romero; Pilar Cristancho
Journal:  Psychiatry (Edgmont)       Date:  2006-01

Review 5.  Frontocingulate dysfunction in depression: toward biomarkers of treatment response.

Authors:  Diego A Pizzagalli
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

6.  A case of illusory own-body perceptions after transcranial magnetic stimulation of the cerebellum.

Authors:  Dennis J L G Schutter; Marjolein P M Kammers; Dorien Enter; Jack van Honk
Journal:  Cerebellum       Date:  2006       Impact factor: 3.847

7.  Baseline brain metabolism in resistant depression and response to transcranial magnetic stimulation.

Authors:  Marie-Laure Paillère Martinot; Jean-Luc Martinot; Damien Ringuenet; André Galinowski; Thierry Gallarda; Frank Bellivier; Jean-Pascal Lefaucheur; Hervé Lemaitre; Eric Artiges
Journal:  Neuropsychopharmacology       Date:  2011-08-17       Impact factor: 7.853

8.  Transcranial magnetic stimulation in the treatment of chronic widespread pain: a randomized controlled study.

Authors:  David H Avery; Paul Zarkowski; Daniel Krashin; Wang-Ku Rho; Chandra Wajdik; Jutta M Joesch; David R Haynor; Dedra Buchwald; Peter Roy-Byrne
Journal:  J ECT       Date:  2015-03       Impact factor: 3.635

9.  Network-Guided Transcranial Magnetic Stimulation for Depression.

Authors:  Marc J Dubin; Conor Liston; Michael A Avissar; Irena Ilieva; Faith M Gunning
Journal:  Curr Behav Neurosci Rep       Date:  2017-02-07

Review 10.  Imaging TMS: antidepressant mechanisms and treatment optimization.

Authors:  Marc Dubin
Journal:  Int Rev Psychiatry       Date:  2017-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.